Table 3.
Significant enriched pathways for genes upregulated in CAF-S4 versus CAF-S1
| GO_Biological Process-Term | Count | % | Genes | P value | FDR |
|---|---|---|---|---|---|
| GO:0001568~blood vessel development | 29 | 7.02 | CAV1, PDGFA, PGF, CSPG4, ENPEP, JAG1, GJA4, PTEN, GJC1, SEMA5A, PTK2, AGT, ANGPT1, ADRA2B, MKL2, FGF1, PLXND1, ANGPT2, COL18A1, FLT1, EPAS1, APOLD1, ITGA4, ARHGAP24, CDH13, LAMA5, PLXDC1, NTRK2, ITGA7 | 5.45E-12 | 9.40E-9 |
| GO:0001525~angiogenesis | 21 | 5.08 | COL18A1, FLT1, EPAS1, PDGFA, PGF, CSPG4, APOLD1, JAG1, ENPEP, ARHGAP24, PTEN, SEMA5A, CDH13, PTK2, LAMA5, PLXDC1, ANGPT1, ADRA2B, PLXND1, FGF1, ANGPT2 | 3.27E-10 | 5.64E-7 |
| GO:0007010~cytoskeleton organization | 35 | 8.47 | DLC1, CAV2, TPPP3, CAV1, PDGFB, CALD1, ARPC5, PRKG1, DAAM2, DSTN, PTK2, EZR, PACSIN2, MICAL1, CAP1, EHD2, FGD4, ARHGDIB, ACTC1, CAP2, ROCK1, MAP1B, ARHGEF17, MYOZ1, VASP, ARHGAP26, MARK1, ARPC1A, PLCE1, EPB41L1, EPS8, LAMA5, MAP2, MYH11, SYNM | 1.10E-9 | 1.90E-6 |
| GO:0007517~muscle organ development | 22 | 5.32 | MEF2C, CAV2, CAV1, MYL4, ACTC1, TBX2, UTRN, RXRG, CACNB2, CSRP2, PTEN, GJC1, FAM65B, MEF2D, LAMA5, PLN, ITGA7, MYH11, RARB, AGRN, MKL2, SGCA | 3.19E-8 | 5.51E-5 |
| GO:0044057~regulation of system process | 25 | 6.05 | CAV1, MYL4, LZTS1, SLC6A1, PPP1R12B, ADA, SYP, EDNRB, KCNQ4, AGT, GUCY1A3, HRC, FLT1, NTF3, EPAS1, MAP1B, ATP1A2, SSTR2, PLCE1, P2RX1, PLN, NTRK2, HSPB7, NPTN, CACNA1C | 3.75E-7 | 6.47E-4 |
| GO:0042692~muscle cell differentiation | 15 | 3.63 | CAV2, ACTC1, NTF3, TBX2, UTRN, CACNB2, MYOZ1, JAG1, CSRP2, AGT, MYH11, SORT1, RARB, AGRN, MKL2 | 1.08E-6 | 0.002 |
| GO:0009190~cyclic nucleotide biosynthetic process | 8 | 1.93 | ADCY3, ADCY4, ADCY1, ADCY5, ADCY6, GUCY1A2, GUCY1A3, GUCY1B3 | 1.35E-6 | 0.002 |
| GO:0042310~vasoconstriction | 7 | 1.69 | ACTG2, EDNRB, CAV1, ACTC1, P2RX1, ACTA2, AGT | 1.72E-6 | 0.003 |
| GO:0009187~cyclic nucleotide metabolic process | 9 | 2.17 | ADCY3, ADCY4, ADCY1, NUDT4, ADCY5, NUDT4P1, ADCY6, GUCY1A2, GUCY1A3, GUCY1B3 | 2.48E-6 | 0.004 |
| GO:0006936~muscle contraction | 16 | 3.87 | MYL4, ACTC1, ACTA2, CALD1, UTRN, VIPR1, GJC1, EDNRB, ACTG2, SSTR2, AGT, MYH11, MYOM1, CACNA1C, HRC, SGCA | 3.69E-6 | 0.006 |
| GO:0050880~regulation of blood vessel size | 10 | 2.42 | CAV2, ACTG2, EDNRB, CAV1, ACTC1, P2RX1, ACTA2, AGT, GUCY1A3, HBB | 3.87E-6 | 0.007 |
| GO:0014706~striated muscle tissue development | 14 | 3.38 | CAV2, ACTC1, CAV1, TBX2, UTRN, RXRG, CACNB2, PTEN, GJC1, PLN, MYH11, RARB, MKL2, AGRN | 5.01E-6 | 0.008 |
| KEGG_Pathway-Term | Count | % | Genes | P value | FDR |
| hsa04270:Vascular smooth muscle contraction | 21 | 5.08 | ADCY3, ADCY4, ADCY1, ROCK1, ACTA2, PPP1R12B, ADCY5, CALD1, ADCY6, MRVI1, PRKG1, KCNMB1, ACTG2, GUCY1A2, PPP1R12A, MYH11, GUCY1A3, GUCY1B3, CACNA1C, MYLK, PLA2G5 | 4.00E-11 | 4.55E-8 |
Enrichment was performed using DAVID web software based on Gene Ontology and KEGG databases. P values are indicated without or after FDR correction